SynthesisFrontiers in oncology2022

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials.

Hangcheng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.